\-\ Texto\\:\\ \ \(0\)\
\-\ pe\\ significant\\ for\\ r\\ eye\\ ptosis\\ and\\ general\\ significant\\ discomfort\\ due\\ to\\ pain\\.\ \(0\)\
\-\ scatter\\ laser\\ treatment\ \(0\)\
\-\ persistent\\ high\\ density\\ in\\ the\\ retro\\ orbital\\ region\\ on\\ the\\ right\\,\\ consistent\\ with\\ a\\ retinal\\ hemorrhage\\.\ \(0\)\
\-\ thickened\\ right\\ peri\\-orbital\\ soft\\ tissues\\ consistent\\ with\\ edema\\.\\ the\\ optic\\ nerve\\ is\\ intact\\.\\ \\ \ \(0\)\
\-\ the\\ left\\ globe\\ is\\ within\\ normal\\ limits\\.\\ \\ the\\ visualized\\ sinuses\\ are\\ within\\ normal\\ limits\\.\\ \\ the\\ osseous\\ structures\\ are\\ intact\\.\ \(0\)\
\-\ retinal\\ hemmorhage\\ secondary\\ to\\ diabetic\\ retinopathy\ \(0\)\
\-\ acute\\ glaucoma\ \(0\)\
\-\ intracranial\\ mass\ \(7\)\
\-\ foreign\\ body\\ or\\ corneal\\ abrasion\ \(0\)\
\-\ viral\\ or\\ bacterial\\ conjunctivitis\ \(0\)\
\-\ keratitis\\ due\\ to\\ herpes\\ simplex\ \(0\)\
\-\ orbital\\ or\\ periorbital\\ cellulitis\ \(0\)\
\-\ ophthalmic\\ zoster\ \(0\)\
\-\ uveitis\ \(9\)\
\-\ temporal\\ arteritis\ \(1\)\
\-\ optic\\ neuritis\ \(15\)\
\-\ 69\\ y\\/o\\ caucasian\\ male\\ with\\ pmhx\\ significant\\ for\\ poorly\\ controlled\\ diabetes\\ mellitus\\,\\ htn\\,\\ and\\ thrombocytopenia\\ \\(most\\ likely\\ secondary\\ to\\ myelofibrosis\\)\\ presented\\ to\\ er\\ with\\ acute\\ onset\\ of\\ unilateral\\ \\(r\\)\\ retroorbital\\ pain\\ without\\ radiation\\.\\ \\ pain\\ is\\ described\\ as\\ sharp\\ and\\ pressure\\ over\\ the\\ right\\ eye\\ with\\ involvement\\ of\\ the\\ frontotemporal\\ region\\ of\\ the\\ head\\.\\ \\ pt\\ denies\\ hx\\ of\\ trauma\\,\\ change\\ in\\ mental\\ status\\,\\ new\\ rashes\\ on\\ the\\ face\\,\\ or\\ recent\\ travel\\.\ \(0\)\
\-\ diabetic\\ retinopathy\\ is\\ a\\ complication\\ of\\ diabetes\\ and\\ a\\ leading\\ cause\\ of\\ blindness\\.\\ it\\ occurs\\ when\\ diabetes\\ damages\\ the\\ tiny\\ blood\\ vessels\\ inside\\ the\\ retina\\,\\ the\\ light\\-sensitive\\ tissue\\ at\\ the\\ back\\ of\\ the\\ eye\\.\\ at\\ first\\,\\ patients\\ with\\ diabetic\\ retinopathy\\ may\\ be\\ asymptomatic\\ with\\ no\\ changes\\ in\\ vision\\.\\ but\\ over\\ time\\,\\ diabetic\\ retinopathy\\ can\\ get\\ worse\\ and\\ cause\\ vision\\ loss\\.\\ diabetic\\ retinopathy\\ usually\\ affects\\ both\\ eyes\\.\ \(0\)\
\-\ diabetic\\ retinopathy\\ has\\ four\\ stages\\:\ \(0\)\
\-\ \\â\\€\\¢\\ mild\\ nonproliferative\\ retinopathy\ \(0\)\
\-\ at\\ this\\ earliest\\ stage\\,\\ microaneurysms\\ occur\\.\\ they\\ are\\ small\\ areas\\ of\\ balloon\\-like\\ swelling\\ in\\ the\\ retina\\'s\\ tiny\\ blood\\ vessels\\.\ \(0\)\
\-\ \\â\\€\\¢\\ moderate\\ nonproliferative\\ retinopathy\\ \ \(0\)\
\-\ as\\ the\\ disease\\ progresses\\,\\ some\\ blood\\ vessels\\ that\\ nourish\\ the\\ retina\\ are\\ blocked\\.\ \(0\)\
\-\ \\â\\€\\¢\\ severe\\ nonproliferative\\ retinopathy\\ \ \(0\)\
\-\ many\\ more\\ blood\\ vessels\\ are\\ blocked\\,\\ depriving\\ several\\ areas\\ of\\ the\\ retina\\ with\\ their\\ blood\\ supply\\.\\ these\\ areas\\ of\\ the\\ retina\\ send\\ signals\\ to\\ the\\ body\\ to\\ grow\\ new\\ blood\\ vessels\\ for\\ nourishment\\.\ \(0\)\
\-\ \\â\\€\\¢\\ proliferative\\ retinopathy\\ \ \(0\)\
\-\ at\\ this\\ advanced\\ stage\\,\\ the\\ signals\\ sent\\ by\\ the\\ retina\\ for\\ nourishment\\ trigger\\ the\\ growth\\ of\\ new\\ blood\\ vessels\\.\\ this\\ condition\\ is\\ called\\ proliferative\\ retinopathy\\.\\ these\\ new\\ blood\\ vessels\\ are\\ abnormal\\ and\\ fragile\\.\\ they\\ grow\\ along\\ the\\ retina\\ and\\ along\\ the\\ surface\\ of\\ the\\ clear\\,\\ vitreous\\ gel\\ that\\ fills\\ the\\ inside\\ of\\ the\\ eye\\.\\ \ \(0\)\
\-\ blood\\ vessels\\ damaged\\ from\\ diabetic\\ retinopathy\\ can\\ cause\\ vision\\ loss\\ in\\ two\\ ways\\:\ \(0\)\
\-\ fragile\\,\\ abnormal\\ blood\\ vessels\\ can\\ develop\\ and\\ leak\\ blood\\ into\\ the\\ center\\ of\\ the\\ eye\\,\\ blurring\\ vision\\.\\ \ \(0\)\
\-\ fluid\\ can\\ leak\\ into\\ the\\ center\\ of\\ the\\ macula\\,\\ the\\ part\\ of\\ the\\ eye\\ where\\ sharp\\,\\ straight\\-ahead\\ vision\\ occurs\\.\\ the\\ fluid\\ makes\\ the\\ macula\\ swell\\ resulting\\ in\\ macular\\ edema\\.\\ it\\ can\\ occur\\ at\\ any\\ stage\\ of\\ diabetic\\ retinopathy\\,\\ although\\ it\\ is\\ more\\ likely\\ to\\ occur\\ as\\ the\\ disease\\ progresses\\.\\ about\\ half\\ of\\ the\\ people\\ with\\ proliferative\\ retinopathy\\ also\\ have\\ macular\\ edema\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ retinopathy\\:\\ 0\\.5714863037191186\ \(0\)\
\-\ retina\\:\\ 0\\.2601412526356343\ \(0\)\
\-\ diabetic\\:\\ 0\\.25557276127898887\ \(0\)\
\-\ the\\:\\ 0\\.23422987226091616\ \(0\)\
\-\ vessels\\:\\ 0\\.2102136875279348\ \(0\)\
\-\ blood\\:\\ 0\\.1922855508045736\ \(0\)\
\-\ eye\\:\\ 0\\.14447338311385655\ \(0\)\
\-\ nonproliferative\\:\\ 0\\.14440583584603245\ \(0\)\
\-\ vision\\:\\ 0\\.13034275903338338\ \(0\)\
\-\ proliferative\\:\\ 0\\.11360285678875746\ \(0\)\
\-\ of\\:\\ 0\\.1060252755827502\ \(0\)\
\-\ nourishment\\:\\ 0\\.0962705572306883\ \(0\)\
\-\ fragile\\:\\ 0\\.0962705572306883\ \(0\)\
\-\ macula\\:\\ 0\\.08895572888099547\ \(0\)\
\-\ new\\:\\ 0\\.08329260889723535\ \(0\)\
\-\ diabetes\\:\\ 0\\.08248007695820218\ \(0\)\
\-\ signals\\:\\ 0\\.08164090053130264\ \(0\)\
\-\ macular\\:\\ 0\\.08164090053130264\ \(0\)\
\-\ blocked\\:\\ 0\\.08039792831343082\ \(0\)\
\-\ orbital\\:\\ 0\\.07920312548785795\ \(0\)\
\-\ can\\:\\ 0\\.07897570565192213\ \(0\)\
\-\ stage\\:\\ 0\\.07190860520383174\ \(0\)\
\-\ inside\\:\\ 0\\.07145633757538931\ \(0\)\
\-\ retinal\\:\\ 0\\.07049630634262335\ \(0\)\
\-\ progresses\\:\\ 0\\.07049630634262335\ \(0\)\
\-\ grow\\:\\ 0\\.06880419967995567\ \(0\)\
\-\ are\\:\\ 0\\.06852781474777908\ \(0\)\
\-\ tiny\\:\\ 0\\.06668650846907412\ \(0\)\
\-\ occur\\:\\ 0\\.06640938151464379\ \(0\)\
\-\ leak\\:\\ 0\\.06439581229204713\ \(0\)\
\-\ cause\\:\\ 0\\.06151505479224498\ \(0\)\
\-\ areas\\:\\ 0\\.061305942109561175\ \(0\)\
\-\ to\\:\\ 0\\.06019805857280127\ \(0\)\
\-\ sharp\\:\\ 0\\.05921298439825539\ \(0\)\
\-\ at\\:\\ 0\\.05684436866362423\ \(0\)\
\-\ center\\:\\ 0\\.05447183212095897\ \(0\)\
\-\ edema\\:\\ 0\\.05385558924730679\ \(0\)\
\-\ with\\:\\ 0\\.053044312829823234\ \(0\)\
\-\ significant\\:\\ 0\\.052135959011067476\ \(0\)\
\-\ optic\\:\\ 0\\.05181969422552533\ \(0\)\
\-\ and\\:\\ 0\\.049757158159832886\ \(0\)\
\-\ is\\:\\ 0\\.049457330574856524\ \(0\)\
\-\ scatter\\:\\ 0\\.04813527861534415\ \(0\)\
\-\ microaneurysms\\:\\ 0\\.04813527861534415\ \(0\)\
\-\ nourish\\:\\ 0\\.04813527861534415\ \(0\)\
\-\ depriving\\:\\ 0\\.04813527861534415\ \(0\)\
\-\ limits\\:\\ 0\\.047566883118405144\ \(0\)\
\-\ occurs\\:\\ 0\\.04746291117802633\ \(0\)\
\-\ it\\:\\ 0\\.046222180382445535\ \(0\)\
\-\ retroorbital\\:\\ 0\\.04599582847345299\ \(0\)\
\-\ in\\:\\ 0\\.0449263228898853\ \(0\)\
\-\ keratitis\\:\\ 0\\.044477864440497734\ \(0\)\
\-\ damages\\:\\ 0\\.044477864440497734\ \(0\)\
\-\ swell\\:\\ 0\\.044477864440497734\ \(0\)\
\-\ intact\\:\\ 0\\.04357035597735532\ \(0\)\
\-\ they\\:\\ 0\\.04301296879372208\ \(0\)\
\-\ send\\:\\ 0\\.042338414298606575\ \(0\)\
\-\ trigger\\:\\ 0\\.042338414298606575\ \(0\)\
\-\ or\\:\\ 0\\.04188399442685341\ \(0\)\
\-\ uveitis\\:\\ 0\\.04152503310443224\ \(0\)\
\-\ gel\\:\\ 0\\.04152503310443224\ \(0\)\
\-\ abrasion\\:\\ 0\\.04082045026565132\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.04082045026565132\ \(0\)\
\-\ myelofibrosis\\:\\ 0\\.04082045026565132\ \(0\)\
\-\ along\\:\\ 0\\.040330711529758534\ \(0\)\
\-\ hemmorhage\\:\\ 0\\.04019896415671541\ \(0\)\
\-\ zoster\\:\\ 0\\.04019896415671541\ \(0\)\
\-\ frontotemporal\\:\\ 0\\.039643025888128985\ \(0\)\
\-\ vitreous\\:\\ 0\\.039643025888128985\ \(0\)\
\-\ ways\\:\\ 0\\.039643025888128985\ \(0\)\
\-\ body\\:\\ 0\\.03961842711248632\ \(0\)\
\-\ thrombocytopenia\\:\\ 0\\.03914011855127464\ \(0\)\
\-\ earliest\\:\\ 0\\.03914011855127464\ \(0\)\
\-\ glaucoma\\:\\ 0\\.03868100012376016\ \(0\)\
\-\ corneal\\:\\ 0\\.03825865211189666\ \(0\)\
\-\ simplex\\:\\ 0\\.03825865211189666\ \(0\)\
\-\ blurring\\:\\ 0\\.03825865211189666\ \(0\)\
\-\ retro\\:\\ 0\\.03750357574623782\ \(0\)\
\-\ damaged\\:\\ 0\\.03750357574623782\ \(0\)\
\-\ blindness\\:\\ 0\\.03716303609080491\ \(0\)\
\-\ laser\\:\\ 0\\.036843148255443575\ \(0\)\
\-\ loss\\:\\ 0\\.036675151674963845\ \(0\)\
\-\ for\\:\\ 0\\.03649142582569937\ \(0\)\
\-\ as\\:\\ 0\\.03627582989748718\ \(0\)\
\-\ ptosis\\:\\ 0\\.03625626248880191\ \(0\)\
\-\ abnormal\\:\\ 0\\.03616647168494014\ \(0\)\
\-\ region\\:\\ 0\\.03600804068722945\ \(0\)\
\-\ rashes\\:\\ 0\\.035985611713282566\ \(0\)\
\-\ likely\\:\\ 0\\.03597315448492999\ \(0\)\
\-\ ophthalmic\\:\\ 0\\.03572816878769466\ \(0\)\
\-\ secondary\\:\\ 0\\.03568118772297784\ \(0\)\
\-\ travel\\:\\ 0\\.035482704376428226\ \(0\)\
\-\ periorbital\\:\\ 0\\.03502358594891374\ \(0\)\
\-\ people\\:\\ 0\\.03502358594891374\ \(0\)\
\-\ arteritis\\:\\ 0\\.03480818733576023\ \(0\)\
\-\ fluid\\:\\ 0\\.034757306007378315\ \(0\)\
\-\ due\\:\\ 0\\.03460324390502502\ \(0\)\
\-\ these\\:\\ 0\\.033994101250253234\ \(0\)\
\-\ fills\\:\\ 0\\.033846161571391406\ \(0\)\
\-\ herpes\\:\\ 0\\.033673144979609805\ \(0\)\
\-\ neuritis\\:\\ 0\\.03350562191595849\ \(0\)\
\-\ mellitus\\:\\ 0\\.03350562191595849\ \(0\)\
\-\ over\\:\\ 0\\.03347303014936334\ \(0\)\
\-\ more\\:\\ 0\\.033055432507747826\ \(0\)\
\-\ get\\:\\ 0\\.03273956420753788\ \(0\)\
\-\ consistent\\:\\ 0\\.03264102572859127\ \(0\)\
\-\ acute\\:\\ 0\\.032565104058794134\ \(0\)\
\-\ pain\\:\\ 0\\.032311874968397096\ \(0\)\
\-\ stages\\:\\ 0\\.03219790614602357\ \(0\)\
\-\ into\\:\\ 0\\.03200050307032024\ \(0\)\
\-\ pmhx\\:\\ 0\\.031825290201581806\ \(0\)\
\-\ cellulitis\\:\\ 0\\.03159073899646526\ \(0\)\
\-\ 69\\:\\ 0\\.03159073899646526\ \(0\)\
\-\ globe\\:\\ 0\\.03136617177406733\ \(0\)\
\-\ controlled\\:\\ 0\\.03136617177406733\ \(0\)\
\-\ this\\:\\ 0\\.03102794929868409\ \(0\)\
\-\ affects\\:\\ 0\\.030843315327278402\ \(0\)\
\-\ supply\\:\\ 0\\.030277430715892832\ \(0\)\
\-\ makes\\:\\ 0\\.030188747396544986\ \(0\)\
\-\ htn\\:\\ 0\\.030015730804763385\ \(0\)\
\-\ right\\:\\ 0\\.029937455967554934\ \(0\)\
\-\ eyes\\:\\ 0\\.02922672163217617\ \(0\)\
\-\ sinuses\\:\\ 0\\.028350895528228403\ \(0\)\
\-\ half\\:\\ 0\\.028350895528228403\ \(0\)\
\-\ advanced\\:\\ 0\\.028289180985027192\ \(0\)\
\-\ bacterial\\:\\ 0\\.028167876026735393\ \(0\)\
\-\ sent\\:\\ 0\\.028167876026735393\ \(0\)\
\-\ called\\:\\ 0\\.028108253547247254\ \(0\)\
\-\ discomfort\\:\\ 0\\.02781984661377449\ \(0\)\
\-\ viral\\:\\ 0\\.02776400976158674\ \(0\)\
\-\ within\\:\\ 0\\.027725587331265282\ \(0\)\
\-\ develop\\:\\ 0\\.027708757599220916\ \(0\)\
\-\ unilateral\\:\\ 0\\.02754638991779948\ \(0\)\
\-\ hx\\:\\ 0\\.02738886976385958\ \(0\)\
\-\ complication\\:\\ 0\\.02733739098195264\ \(0\)\
\-\ foreign\\:\\ 0\\.027286409587357417\ \(0\)\
\-\ poorly\\:\\ 0\\.027185901152431986\ \(0\)\
\-\ face\\:\\ 0\\.027136355874867867\ \(0\)\
\-\ part\\:\\ 0\\.02689537640504657\ \(0\)\
\-\ caucasian\\:\\ 0\\.026755900444096502\ \(0\)\
\-\ leading\\:\\ 0\\.026755900444096502\ \(0\)\
\-\ mental\\:\\ 0\\.026232178353257966\ \(0\)\
\-\ that\\:\\ 0\\.0261239051604976\ \(0\)\
\-\ thickened\\:\\ 0\\.025389203512847236\ \(0\)\
\-\ disease\\:\\ 0\\.025269204981593758\ \(0\)\
\-\ worse\\:\\ 0\\.025215044690669892\ \(0\)\
\-\ surface\\:\\ 0\\.02511324346306556\ \(0\)\
\-\ resulting\\:\\ 0\\.025046451010540823\ \(0\)\
\-\ their\\:\\ 0\\.024980493485553337\ \(0\)\
\-\ pe\\:\\ 0\\.024883077796330734\ \(0\)\
\-\ growth\\:\\ 0\\.02481911903393108\ \(0\)\
\-\ normal\\:\\ 0\\.024578656790249637\ \(0\)\
\-\ described\\:\\ 0\\.02442127888448503\ \(0\)\
\-\ four\\:\\ 0\\.024391883079807407\ \(0\)\
\-\ denies\\:\\ 0\\.02427591064677243\ \(0\)\
\-\ intracranial\\:\\ 0\\.024218866488025806\ \(0\)\
\-\ general\\:\\ 0\\.024162432438928075\ \(0\)\
\-\ condition\\:\\ 0\\.024051343424374497\ \(0\)\
\-\ osseous\\:\\ 0\\.02402393280017387\ \(0\)\
\-\ tissues\\:\\ 0\\.023731455589013167\ \(0\)\
\-\ many\\:\\ 0\\.023731455589013167\ \(0\)\
\-\ where\\:\\ 0\\.02365442453783652\ \(0\)\
\-\ visualized\\:\\ 0\\.023503656186855654\ \(0\)\
\-\ persistent\\:\\ 0\\.02319105940321753\ \(0\)\
\-\ temporal\\:\\ 0\\.023121477736095093\ \(0\)\
\-\ pressure\\:\\ 0\\.022918074394838825\ \(0\)\
\-\ change\\:\\ 0\\.02280837120650268\ \(0\)\
\-\ structures\\:\\ 0\\.02261647612126425\ \(0\)\
\-\ moderate\\:\\ 0\\.022595578932395746\ \(0\)\
\-\ about\\:\\ 0\\.02253337939141925\ \(0\)\
\-\ er\\:\\ 0\\.02251280808547044\ \(0\)\
\-\ clear\\:\\ 0\\.02182107291140682\ \(0\)\
\-\ involvement\\:\\ 0\\.02178517798867766\ \(0\)\
\-\ pt\\:\\ 0\\.021661434518461142\ \(0\)\
\-\ nerve\\:\\ 0\\.021472660349675276\ \(0\)\
\-\ status\\:\\ 0\\.02100511968048034\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.02049100355918259\ \(0\)\
\-\ although\\:\\ 0\\.02049100355918259\ \(0\)\
\-\ recent\\:\\ 0\\.020380206138301132\ \(0\)\
\-\ first\\:\\ 0\\.0203121208930975\ \(0\)\
\-\ swelling\\:\\ 0\\.020258278249450493\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.020152213707543703\ \(0\)\
\-\ back\\:\\ 0\\.02007404141416675\ \(0\)\
\-\ density\\:\\ 0\\.01995891248417769\ \(0\)\
\-\ radiation\\:\\ 0\\.019946274075039568\ \(0\)\
\-\ several\\:\\ 0\\.01974807111900505\ \(0\)\
\-\ any\\:\\ 0\\.01945255530523084\ \(0\)\
\-\ onset\\:\\ 0\\.01932759388655932\ \(0\)\
\-\ severe\\:\\ 0\\.01905413719058431\ \(0\)\
\-\ usually\\:\\ 0\\.018948603006833816\ \(0\)\
\-\ some\\:\\ 0\\.01893816475754933\ \(0\)\
\-\ changes\\:\\ 0\\.018190741088362473\ \(0\)\
\-\ when\\:\\ 0\\.01818169818419109\ \(0\)\
\-\ on\\:\\ 0\\.018180989823830946\ \(0\)\
\-\ head\\:\\ 0\\.017951863082435595\ \(0\)\
\-\ two\\:\\ 0\\.01787458131099601\ \(0\)\
\-\ time\\:\\ 0\\.01784059386148892\ \(0\)\
\-\ presented\\:\\ 0\\.017552186928016158\ \(0\)\
\-\ trauma\\:\\ 0\\.017480504618597598\ \(0\)\
\-\ high\\:\\ 0\\.017106450534792202\ \(0\)\
\-\ mild\\:\\ 0\\.017062418012566843\ \(0\)\
\-\ patients\\:\\ 0\\.016932483130629884\ \(0\)\
\-\ both\\:\\ 0\\.016784828993717058\ \(0\)\
\-\ soft\\:\\ 0\\.016024208594669243\ \(0\)\
\-\ without\\:\\ 0\\.0158762310535247\ \(0\)\
\-\ tissue\\:\\ 0\\.01578939640113703\ \(0\)\
\-\ most\\:\\ 0\\.015664569362122648\ \(0\)\
\-\ small\\:\\ 0\\.015526214993969344\ \(0\)\
\-\ may\\:\\ 0\\.015146899634134738\ \(0\)\
\-\ have\\:\\ 0\\.0150362342503704\ \(0\)\
\-\ but\\:\\ 0\\.014884133963703899\ \(0\)\
\-\ treatment\\:\\ 0\\.014337877410297123\ \(0\)\
\-\ also\\:\\ 0\\.014157831999982447\ \(0\)\
\-\ has\\:\\ 0\\.013748467590370055\ \(0\)\
\-\ male\\:\\ 0\\.013401350993481411\ \(0\)\
\-\ by\\:\\ 0\\.012781893930251151\ \(0\)\
\-\ be\\:\\ 0\\.012210068824794078\ \(0\)\
\-\ from\\:\\ 0\\.011954152292458657\ \(0\)\
\-\ mass\\:\\ 0\\.01149711602214023\ \(0\)\
\-\ left\\:\\ 0\\.01026751602348993\ \(0\)\
\-\ no\\:\\ 0\\.009787938741115566\ \(0\)\
